Search the Newsreel

Perfectech to Approve Interim Results and Mull Dividend at August Board Meeting

Why Frontera Energy Corp stock is gaining today

Judge approves $3.75 million Lifecore investor settlement

A federal judge has granted final approval for a $3.75 million settlement in a securities class action lawsuit against Lifecore Biomedical Inc. Investors accused Lifecore of making false statements about its financial condition and internal accounting controls, which led to a stock price drop …

Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Manager of Investor Relations - Stephanie Diaz President and Chief Executive Officer - Paul Josephs Chief Financial Officer - Ryan Lake Full Conference Call Transcript Operator: Good morning, …

Perfect Corp. (NYSE:PERF) Short Interest Update

Frontera Energy Sets Date for Q2 2026 Results and Investor Call

Is It Too Late To Consider Buying Jeena Sikho Lifecare Limited (NSE:JSLL)?

Frontera Energy Q2 Results: Earnings call set for Aug 14

Frontera Energy Provides Notice of Second Quarter 2026 Financial Results Conference Call

Why It Might Not Make Sense To Buy Perfect Medical Health Management Limited (HKG:1830) For Its Upcoming Dividend

Perfect Presentation for Commercial Services Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Frontera Energy Corporation (TSX:FEC) Stock Falls as Strategic Transition and Energy Market Risks Pressure Sentiment

Jeena Sikho Lifecare Shares Investor Deck Ahead Q1 FY27 Earnings Call

Jeena Sikho Lifecare revenue surges 29% in Q1FY27 on strong service demand

Perfect Corp (PERF) Earnings Forecast: Future EPS & Revenue Growth Estimates

Great-West Lifeco Inc. (TSE:GWO) Given Average Recommendation of "Moderate Buy" by Brokerages

Will Great-West Lifeco (TSX:GWO) Maintain Its Financial Sector Momentum?

Perfect Medical Wins Strong Shareholder Backing at AGM

Lifecore Biomedical Releases Q2 2026 Financial Results

Lifecore Biomedical, Inc. (LFCR) reported its Q2 2026 financial results, narrowing its loss per share to -$0.19 and exceeding revenue expectations with $34.2 million. Despite beating estimates, the company experienced a 6.2% revenue decline year-over-year due to softness in its CDMO segment. Management provided …

Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Lifecore Biomedical (NASDAQ:LFCR) reported its quarterly earnings, exceeding analyst estimates with an EPS loss of $0.19, $0.03 better than expected, and revenue of $34.17 million, surpassing the $32.02 million forecast. Despite a year-to-date revenue decline and widened net loss, the company reaffirmed its 2026 …

Riachuelo (RIAA3): 2T com resultados fortes

Excelerate Energy Reports Strong Second Quarter 2026 Results

THE WOODLANDS, Texas, August 05, 2026--(BUSINESS WIRE)--Excelerate Energy, Inc. (NYSE: EE) (Excelerate or the Company) today reported its financial results for the second quarter ended June 30, 2026. RECENT HIGHLIGHTS Reported Net Income of $50.1 million for the second quarter Reported Adjusted EBITDA of …

LFCR Stock Price and Chart — NASDAQ:LFCR

Lifecore Biomedical, Inc. (LFCR) is a pharmaceutical company specializing in hyaluronan-based products. Its stock price is currently $5.01, with a market capitalization of $189.64 million. The company's recent earnings report showed declining revenue and profit year-over-year, but management reaffirmed 2026 guidance due to cost …

Lifecore Biomedical Inc expected to post a loss of 22 cents a share - Earnings Preview

Lifecore Biomedical Inc is anticipated to report a loss of 22 cents per share, according to an earnings preview. This forecast is based on information shared through TradingView News, indicating an upcoming financial announcement for the company.

Lifecore Biomedical, Inc. reports results for the quarter ended June 30 - Earnings Summary

Lifecore Biomedical, Inc. has reported its financial results for the quarter that ended on June 30. The article, sourced from Reuters via TradingView News, provides an earnings summary for the company. Readers are encouraged to access the full report for detailed information.

Lifecore Biomedical Q2 FY26 net loss widens to $6.2 million; revenue falls 6.2% to $34.2 million

Lifecore Biomedical reported a wider GAAP net loss of $6.2 million in Q2 FY26, with revenue decreasing by 6.2% to $34.2 million. GAAP gross profit also fell, and non-GAAP adjusted EBITDA saw a slight decrease. Despite these financial challenges, the company signed six new …

Lifecore Signs Six New Programs, Including Two Commercial-Stage

Lifecore Biomedical reported Q2 2026 revenues of $34.2 million, a 6.2% decrease year-over-year, and a net loss of $6.2 million. Despite the revenue decline, the company reaffirmed its 2026 guidance for revenues of $120–$125 million and Adjusted EBITDA of $20.5–$25 million, citing strong business …

Lifecore Biomedical (NASDAQ: LFCR) Q2 revenue slips as 2026 guidance reaffirmed

Lifecore Biomedical reported a decline in Q2 2026 revenue to $34.2 million and an increased net loss of $6.2 million, despite growth in hyaluronic-acid manufacturing. The company reaffirmed its full-year 2026 guidance for revenue ($120-$125 million) and Adjusted EBITDA ($20.5-$25 million), highlighting a strong …

Lifecore Biomedical, Inc. Reaffirms Earnings Guidance for the Calendar Year 2026

Lifecore Biomedical, Inc. has reaffirmed its earnings guidance for the calendar year 2026, expecting revenue to be in the range of $120 million to $125 million. This announcement was made on August 5, 2026, coinciding with their Q2 2026 earnings call. The company specializes …

Great-West Lifeco (TSE:GWO) Hits New 12-Month High - What's Next?

Jeena Sikho Lifecare launches Amrit Dhara Drops 20 ml

Insider Selling: Frontera Energy (TSE:FEC) Insider Sells C$23,715.00 in Stock

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore

Faruqi & Faruqi, LLP is investigating potential securities claims against Lifecore Biomedical, Inc. (NASDAQ: LFCR) on behalf of investors who suffered losses exceeding $75,000 between October 7, 2020, and March 19, 2024. The investigation stems from allegations that Lifecore made false or misleading statements …